Mode
Text Size
Log in / Sign up
Phase 4 N=18 Randomized Quadruple-blind

Pregabalin on Colonic Motor and Sensory Function in Constipation Predominant Irritable Bowel Syndrome

Irritable Bowel Syndrome

Enrolled (actual)
18
Serious AEs
0.0%
Results posted
Mar 2014
Primary outcome: Primary: Colonic Compliance — 18.96; 16.86; 15.99; 15.75 mm Hg

Study Design & Population

Study type
Interventional
Phase
Phase 4
Interventions
Pregabalin (Drug); Placebo (Drug)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
Mayo Clinic
Primary completion
Feb 2013

Outcome Measures

OutcomeResultp-value
PRIMARY
Colonic Compliance
18.96; 16.86; 15.99; 15.75
PRIMARY
Postprandial Colonic Tone [Reported as the Symmetric Percent [Change} in Baseline Colonic Barostat Balloon Volume
-22.34; -24.45
PRIMARY
Sensory Threshold for Pain
36.0; 38.0
PRIMARY
Overall Sensory Ratings in Response to 16, 24, 30 and 36 mm Hg Distensions.
53.0; 52.3; 57.43; 59.60; 64.0; 60.3
SECONDARY
Fasting Colonic Tone
120.4; 116.8
SECONDARY
Colonic Motility Index
13.69; 12.27; 11.72; 10.21
SECONDARY
Post-treatment Sensory Threshold for Gas
24.0; 19.2

Summary

The general aim of the current study is to describe the effect of pregabalin on colonic and sensory functions in adults with constipation predominant irritable bowel syndrome (IBS-C). Study hypotheses: 1. Single-dose pregabalin 200mg increases sensation thresholds and decreases sensation ratings in response to balloon distension in the colon relative to pre-pregabalin treatment. 2. Single-dose pregabalin 200 mg will increase colonic compliance and decrease colonic pain and gas thresholds in patients with irritable bowel syndrome constipation predominant. 3. Single-dose pregabalin 200mg increases the colonic phasic and tonic response to a standardized meal.

Eligibility Criteria

Inclusion criteria

  • Male or females with Constipation Predominant IBS, age 18-65

Exclusion criteria

  • Abdominal surgery other than appendectomy, laparoscopic cholecystectomy, cesarean section, vaginal or laparoscopic hysterectomy or tubal ligation
  • Uncontrolled hypertension
  • Use of medications that may interact with the study medication
  • Use of any of the study medications within the past 30 days
  • Pregnancy
  • History of chronic renal insufficiency (serum creatinine >1.5mg/dL)
  • Psychiatric or psychologic dysfunction
  • Current pelvic floor dysfunction
  • diagnosis of lactose intolerance
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01331213). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search